Mease et al. TYK2i Deucravacitinib in PsA. Phase 2 RCT 52 week results. PASDAS, DAPSA efficacy maintained through week 52. No new safety concerns. @RheumNow #ACR22 Abstr#1598 https://t.co/sRKkgkYtQJ https://t.co/YMXMEH3wsq
Links:
Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 In…
https://acrabstracts.org/abstract/safety-and-efficacy-of-deucravacitinib-an-ora…
14-11-2022